ProfileGDS5678 / 1417962_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 81% 92% 93% 96% 89% 94% 96% 97% 96% 80% 94% 93% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5047692
GSM967853U87-EV human glioblastoma xenograft - Control 25.762581
GSM967854U87-EV human glioblastoma xenograft - Control 37.5833992
GSM967855U87-EV human glioblastoma xenograft - Control 48.1248193
GSM967856U87-EV human glioblastoma xenograft - Control 58.7225696
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7008689
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7805194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.9216496
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.3320197
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.9054796
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.658680
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3072194
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9846693
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.311491